奥精国际健康科研基地  

Allgens International Health Research Base

出　　处：《走向世界》2021年第39期38-38,共1页Openings

摘　　要：该项目由国家高新技术企业——北京奥精医药科技有限公司和潍坊凤翔金融投资控股有限公司共同投资建设,总投资9亿元,占地面积98亩,总建筑面积9.2万平方米。项目全部投产后将是亚洲最大的胶原蛋白和医用仿生材料研发生产基地,主要生产胶原蛋白、人工硬脑膜、神经修复导管、仿生人工骨、人工再生皮肤等八大类产品。预计年可实现收入50亿元,利税10亿元,新增就业岗位2500个,是山东省新旧动能转换重大项目库第一批优选项目,获得山东省重大科技专项奖励。奥精公司将联合国内知名基金,通过并购等方式。Jointly invested by the national high-tech enterprises of Beijing Allgens Pharmaceutical Technology Co.,Ltd.and Weifang Fengxiang Financial Investment Holding Co.,Ltd..this project has an investment of 900 million yuan,an area of 98 mu,and a total floor area of 9,2000 square meters.After it is put into operation.this project will be the largest R & D and production base of collagen and medical bionic materials in Asia,mainly producing eight categories of products including collagen,artificial dura mater,nerve repair catheter,artificial bionic bones and artificial regenerated skins.The annual income is estimated to be five billion yuan.and the profit and tax is estimated to be one billion yuan.

关 键 词：新旧动能转换 研发生产基地 重大科技专项 科研基地 占地面积 神经修复 仿生材料 人工硬脑膜 

分 类 号：F42[经济管理—产业经济]